RWJF's Fox in as new HHS CTO

Susannah Fox, entrepreneur-in-residence at the Robert Wood Johnson Foundation, has been named the new chief technology officer of the Department of Health and Human Services (HHS).

Fox also was previously director of the Pew Research Center’s health and technology portfolio.

In a blog post on the HHS IdeaLab, Fox wrote that she intends to build on the work of her predecessors: Bryan Sivak, who was both CTO and entrepreneur-in-residence; and Todd Park, former athenahealth executive and the department's first CTO.

In her post, Fox detailed the following three “possibilities” that led her to accept the position:

1. To continue and expand Park’s data liberacion work. “I’m a health data geek from way back and think we’ve only just begun to harness its power."

2. To “nurture the entrepreneurial spirit” Sivak's "IdeaLab team ignited across all 11 HHS operating divisions. Their participatory approach to solving problems matches my own methods.” 

3. To “shine a spotlight on the role that citizens play in strengthening the health of our country." She also noted that the internet has given individuals greater access to information as well as access to each other.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.